Salute e Benessere

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in…

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. in October 2024PARIS, FRANCE, 15 November 2024Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo ®(elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE ®study at the...
Nasdaq GlobeNewswire
15/11/2024

Gene Editing Market to Hit USD 7.59 Billion by 2029 with 10.2% CAGR |…

Browse in-depth TOC on "Gene Editing Market" Browse in-depth TOC on "Gene Editing Market" 636 - Tables 65 - Figures 497 - Pages Based on Offerings,the market is divided into products and services segments. The products segment accounted for the largest share of the gene editing market in 2023. The large share of products is majorly due to the reagents, kits, and other consumables that are used in CRISPR, TALEN, ZFN and other gene editing technologies for applications such...
PR Newswire
15/11/2024

Healthcare leaders gather at House of Commons to discuss productivity-boosting…

With £2bn pledged to help digitise the NHS and bring down waiting lists, such time-saving tech is high on healthcare's agenda. Trust Chief Executive Matthew Hopkins introduced the session, which was hosted by David Burton-Sampson, MP for Southend West and Leigh, and saw technology strategists and users share their experiences of digitising vital healthcare operations. With £2bn pledged to help digitise the NHS and bring down waiting lists, such time-saving tech is high on healthcare's agenda...
PR Newswire
15/11/2024

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in…

"Paladin has an experienced and dedicated team, and we're pleased to work with them to introduce Wynzora® Cream in Canada," said Jesper J. Lange, Chief Executive Officer, MC2 Therapeutics. "The agreement aligns with our strategy to make Wynzora® Cream available to as many patients suffering from plaque psoriasis as possible globally." "Paladin has an experienced and dedicated team, and we're pleased to work with them to introduce Wynzora ®Cream inCanada," saidJesper…
PR Newswire
15/11/2024

Navamedic ASA: Amendments to loan agreements with Observe Medical ASA

Navamedic has agreed to the following amendments to the two loan agreements: Navamedic has agreed to the following amendments to the two loan agreements: Navamedic has agreed to convertNOK 16,354,815.20of Loan 1 into shares in Observe Medical ASA at a subscription price ofNOK 0.40per share, provided that Observe Medical completes its contemplated subsequent offering at a subscription price ofNOK 0,40with gross proceeds of at leastNOK 1.500.000. In total 40,887,038 new shares...
PR Newswire
15/11/2024

Plastic Injection Molding Machine Market worth $14.78 billion by 2030 -…

Browse in-depth TOC on "Plastic Injection Molding Machine Market" Browse in-depth TOC on "Plastic Injection Molding Machine Market" 308 – Tables 55 – Figures 264 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72063702 The all-electric machine type segment is the fastest growing segment, in terms of value, of the global plastic injection molding machine market during the forecast period. The all-electric machine type segment is...
PR Newswire
15/11/2024

EUBP welcomes the inclusion of soil-biodegradable products in the Fertilising…

The FPR sets high requirements in terms of environmental safety. European Bioplastics (EUBP) welcomes the inclusion of soil-biodegradable mulch films, coating agents, and water retention polymers in the FPR and the key role given to existing standards concerning the biodegradation of mulch films in soil. The newly defined biodegradability criteria are strict but scientifically sound and will fully demonstrate that certified soil-biodegradable mulch films are environmentally safe while...
Nasdaq GlobeNewswire
15/11/2024

Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option…

Numab to receive R&D funding for the preclinical development of ND081Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global development up to clinical POC HORGEN, Switzerland and TOKYO, Nov.15, 2024(GLOBE NEWSWIRE) -- Numab Therapeutics AG(“Numab”), a clinical stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, and Kaken Pharmaceutical Co...
Nasdaq GlobeNewswire
15/11/2024

International Cancer Organizations Present Collaborative Work During Oncology…

"NCCN is honored to participate in this important meeting," said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. "China is one of the top three countries in the world in terms of number of registered users for our website and downloads of NCCN Guidelines. We are grateful that our evidence-based expert consensus-driven recommendations are being utilized to guide and improve care for people with cancer throughout China and all of Asia." "NCCN is honored to participate in…
PR Newswire
15/11/2024

Aino Health AB (publ): interim report january-september 2024

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.Aino reveals the main reasons for absence at workJanuary – September 2024 Net sales were KSEK 17 941 (17 605)Profit/loss after financial items was KSEK -6 464 (-6 812)Earnings per share were SEK-0,1 (-0,2)July – September 2024Net sales were KSEK 5 712 (5 633)Profit/loss after financial items was KSEK -1 504 (-1 215)Earnings...
Nasdaq GlobeNewswire
15/11/2024

Implantica publishes Interim Report January - September 2024 (Q3)

Significant events after the end of the period Significant events after the end of the period Financial summary third quarter 2024 First nine months Telephone conference Implantica will hold a teleconference on15 November 2024at 15:00 (CET) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: WebcastIf you wish to participate via webcast, please use...
PR Newswire
15/11/2024

Noster Inc research: Celebrating Breakthroughs in Gut Microbiome

On October 10, the Symposium at NOSTER's Kyoto headquarters featured this year's winners, who shared insights on their pioneering discoveries related to the gut microbiome and its impact on health. Topics covered included the intricate interactions between gut bacteria, host organisms, and immune cells, as well as the potential of microbiome-based therapies. OnOctober 10, the Symposium at NOSTER'sKyotoheadquarters featured this year's winners, who shared insights on their pioneering...
PR Newswire
15/11/2024

Bavarian Nordic Announces Interim Results for the First Nine Months of 2024

COPENHAGEN, Denmark, November 15, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of 2024. Revenue for the first nine months was DKK 3,622 million, and the operating profit (EBITDA) was DKK 692 million.Revenue from Travel Health increased by 18% to DKK 1,892 million compared to the first nine months of 2023 and revenue from Public Preparedness was DKK 1,549 million, which is...
Nasdaq GlobeNewswire
15/11/2024

Sandoz receives European Commission approval for Afqlir® (aflibercept), further…

MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadershipBasel, November 15, 2024 –Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the European...
Nasdaq GlobeNewswire
15/11/2024

Press Release: Dupixent sBLA accepted for FDA review for the treatment of…

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesFDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decadeParis and Tarrytown, NY, November 15, 2024...
Nasdaq GlobeNewswire
15/11/2024

Presbyopia Treatment Market Set to Reach New Heights with New Therapies and…

As per DelveInsight's assessment, the total prevalent cases of presbyopia in the 7MM were ~325 million in 2023. These cases are expected to increase at a significant CAGR of 1.1% during the forecast period i.e., 2024–2034. Based on severity, presbyopia was bifurcated into mild and moderate to severe presbyopia, in EU4 and the UK, moderate to severe presbyopia accounted for the maximum number of cases, which was approximately 95 million. As per DelveInsight's assessment, the total prevalent...
PR Newswire
14/11/2024

miraDry Wins 2024 SHAPE Beauty Award for Excellence in In-Office Aesthetic…

miraDry's inclusion in this elite list highlights its unique contribution to the world of non-invasive aesthetic treatments. By addressing common concerns like excessive sweating and body odor in a way that is both effective and long-lasting, miraDry provides an accessible solution for people seeking to feel more confident and comfortable in their skin. miraDry's inclusion in this elite list highlights its unique contribution to the world of non-invasive aesthetic treatments. By addressing...
PR Newswire
14/11/2024

Akari Therapeutics Announces Successful Completion of Merger of Akari…

- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and LONDON, Nov.14, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) announces the completion of the merger (the Merger) of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. (Peak Bio), creating an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies. The combined entity will continue the two...
Nasdaq GlobeNewswire
14/11/2024

CHMP issues positive recommendation for approval of lecanemab in the EU

The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) or are non-carriers of the Apolipoprotein E ε4 (ApoE ε4) gene. The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) or are non-carriers of the...
PR Newswire
14/11/2024

Spineway : a week dedicated to medical excellence with more than 20 surgeons…

Press release Ecully, November 14, 2024 – 6 p.m.Spineway: a week dedicated to medical excellence with more than 20 surgeons trained The Spineway Group, a, specialist in innovative implants for the treatment of severe spine disorders, organized a week of training dedicated to medical education from November 4 to 8, 2024. Through practical sessions in the operating room and on anatomical specimens in the laboratory, this intensive program trained over 20 international...
Nasdaq GlobeNewswire
14/11/2024

Press Release: Sequana Medical Announces New Share Capital Amount and New Number…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARESGhent, Belgium, 14 November 2024 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of a contribution in kind of receivables outstanding under the loan agreement entered into on 27 July 2020 between the Company and Belfius Insurance NV (as…
Nasdaq GlobeNewswire
14/11/2024

Groupe Casino - Nombre de droits de vote et d'actions 31-10-2024

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 4 009 397,13 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 31 octobre 2024(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers)Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote exerçables en...
Nasdaq GlobeNewswire
14/11/2024

Press Release: Sarclisa recommended for EU approval by the CHMP to treat…

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd aloneIf approved, Sarclisa would be the first anti-CD38 therapy in the EU available for use in combination with VRd for adult patients with transplant-ineligible NDMM Paris, November 14, 2024...
Nasdaq GlobeNewswire
14/11/2024

Eisai Receives Positive Opinion from the CHMP in the European Union for…

TOKYO and CAMBRIDGE, Mass., Nov.14, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment...
Nasdaq GlobeNewswire
14/11/2024
Altri  Comunicati